LONDON’S GLOBAL UNIVERSITY
HCC UK First Annual Conference
The Atrium, Royal Free Hospital, Pond Street, London, NW3 2QG
Thursday 31 March – Friday 1 April 2016
Programme Organisers
Programme Description
Professor of Experimental Cancer Medicine and Consultant Medical Oncologist,
Department of Oncology, Royal Free Hospital and UCL Cancer Institute
The programme is aimed at covering the clinical management,
current areas of controversy and the latest in fundamental
research in the field of Hepatocellular carcinoma.
Tim Meyer
James O’Beirne
Consultant in Hepatology, Royal Free Hospital
Aileen Marshall
Consultant in Hepatology, Royal Free Hospital
State-of-the-art lectures and ‘live’ multidisciplinary sessions
will be included to maximise audience participation.
Registration Fee
Massimo Pinzani
Consultants £120 Conference Coordinator
Oncologists, Hepatologists and Gastroenterologists, Non-medical
Health Professionals and Basic Scientists interested in liver cancer.
Mekala Gunaratnam
Endorsement
Consultant Hepatologist, Sheila Sherlock Chair in Hepatology,
UCL Institute for Liver and Digestive Health, University College London
UCL Experimental Cancer Medicine Centre, UCL Cancer Institute
Activity and Learning Objectives
To understand the latest innovations for the treatment
of hepatocellular carcinoma.
To understand advances in the molecular biology
of hepatocellular carcinoma.
To gain insight into the areas of controversy in the
management of hepatocellular carcinoma.
BASL
British Association for the Study of the Liver
Trainees/Nurses/Scientists £65
Target Audience
This event is endorsed by the European Association for the Study
of the Liver (EASL) and the British Association for the Study of the
Liver (BASL).
Accreditation and Credit Designation
HCC UK – First Annual Conference has been approved by the
Federation of the Royal Colleges of Physicians of the United
Kingdom for 12 category 1 (external) CPD credit(s). Certificate of
attendance will be provided to all participants upon request.
Day 1
8.30–9.00
Registration
9.00–10.50
Clinical Management and Current Controversies – Chair Tim Meyer
9.00–9.10
9.10–9.30
9.30–9.50
9.50–10.10
10.10–10.30
10.30–10.50
Welcome – Royal Free Hospital Chief Executive David Sloman
Transplantation – refining patient selection Aileen Marshall
Surgical resection for HCC – selection and outcome Max Malago
Transarterial embolization; who, how, when and why? Marcus Peck-Radosavljevic
Radioembolisation – who is it good for? Bruno Sangro
Role of Specialist Nurse Pam O’Donoghue
10.50–11.10
Morning Coffee
11.10–12.50
Progress with Systemic Therapy – Chair James O’Beirne
11.10–11.30
11.30–11.50
11.50–12.10
12.10–12.30
12.30-12.50
Recent results and trials in progress Tim Meyer
Immunotherapy – science Sergio Quezada
Immunotherapy – clinical Daniel Palmer
Novel approaches – preclinical models Rajiv Jalan
Gene therapy for HCC Amit Nathwani
12.50–13.45
Lunch
13.45–15.25
Molecular pathogenesis – Chair Aileen Marshall
13.45–14.05
14.05–14.25
14.25–14.45
14.45–15.05
15.05–15.25
Molecular pathogenesis– implications for therapy Jean-Charles Nault
Epigenetics – relevance to HCC Chrissie Thirlwell
The role of stem cells in the pathogenesis of HCC Luke Boulter
Liver fibrosis in the context of HCC Massimo Pinzani
Diagnostic challenges for the pathologist Stefan Hubscher
15.25–15.45
Afternoon Tea
15.45–16.35
Debates – Chair Massimo Pinzani
16.00–15.30
15.30–16.15
16.15–16.25
15.25–16.40
16.40–16.55
16.55–17.10
Surveillance for HCC – In favour James O’Beirne
Surveillance for HCC - Against Ian Rowe
Audience discussion and voting All
Biopsy for HCC – In favour Alberto Quaglia
Biopsy Against – Against Helen Reeves
Audience discussion and voting All
17.10
Close
Day 2
Friday 1 April 2016
8.30–9.00
Arrival
9.00–10.20
Clinical Decision Making – Live Multidisciplinary Meeting – Chair Brian Davidson
Pathology TuVinh Luong
Radiology Dominic Yu
Radioembolization Bruno Sangro
Surgery Nigel Heaton / Brian Davidson
Oncology Philip Johnson / Deb Sarker
Hepatology Graeme Alexander / Helen Reeves
10.20–10.40
Morning Coffee
10.40–12.00
Staging and Molecular Markers – Chair Chrissie Thirlwell
11.00–11.20
11.20–11.40
11.40–12.00
12.20–12.40
Staging and stratification Philip Johnson
Prognostic biomarkers Shahid Khan
Predictive markers Julien Edeline
Novel diagnostics – circulating DNA Tim Forshew
Non-coding RNAs as biomarkers in liver cancer Chiara Braconi
12.40–13.30Lunch
13.30–14.30
Epidemiology and Management Challenges - Chair Dinesh Sharma
13.30–13.50
13.50–14.10
14.10–14.30
Epidemiology Michel Coleman
Treating viral hepatitis in patients with HCC Doug MacDonald
Mixed HCC/CC how should we treat them? Paul Ross
14.30
Close
programme
Thursday 31 March 2016